Transdermal Diagnostics (TD), a Bristol-based MedTech spin-out, has secured £1.1 million to develop the world’s first 100% needle-free platform for blood sugar monitoring. The company’s technology will allow pain-free and continuous monitoring of sugar levels Read More
